Neurodevelopment and Growth 2 Years After Probiotic Supplementation in Extremely Preterm Infants: A Randomised Trial
Acta Paediatrica · 2025
DOI: 10.1111/apa.70030 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Acta Paediatrica, 2025. Verfasst von Erik Wejryd und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Children's and Women's Health, Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden. Hauptthemen laut MEDLINE: Probiotics, Infant, Extremely Premature, Child Development, Limosilactobacillus reuteri. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Forskningsrådet i Sydöstra Sverige, Region Östergötland, Ekhagastiftelsen.
Themen: Neonatologie
Abstract (Originalsprache)
Aim
To assess neurodevelopment and growth at 2 years corrected age in children born extremely preterm, supplemented with Limosilactobacillus reuteri or placebo.
Methods
Design: Secondary analysis of register data after randomised double‐blind placebo‐controlled trial.
Setting
Inclusion at two neonatal intensive care units in Sweden. Local follow‐up per national guidelines. Subjects: 134 infants born at 23–27 weeks' gestation with a birth weight < 1000 g.
Intervention
Daily enteral supplementation with placebo or Limosilactobacillus reuteri DSM 17938 (2.5 × 10 8 colony forming units), from within 72 h after birth to postmenstrual week 35–36. Main outcome measures: Bayley‐III developmental assessment and auxology at 24 ± 3 months corrected age.
Results
Follow‐up data were available for 110 of 117 surviving participants, and 85 children were assessed with Bayley‐III. Mean language score after supplementation with L. reuteri was 90 (95% confidence interval: 85–95) compared to 83 in the placebo group (95% CI: 78–88), p = 0.04. No other significant differences in neurodevelopment or growth were observed.
Conclusion
Supplementation with L. reuteri in extremely preterm infants was not associated with altered growth nor general neurodevelopmental outcomes at 2 years while language index was improved. This is interesting given previously reported early improved growth of head circumference.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Children's and Women's Health, Department of Biomedical and Clinical Sciences, Linköping University, Linköping, Sweden.
- Department of Paediatrics, Vrinnevi Hospital, Norrköping, Sweden.
- Department of Neonatology, Astrid Lindgren Children's Hospital, Karolinska University Hospital, Stockholm, Sweden.
- Crown Princess Victoria Children's Hospital, Linköping University Hospital, Linköping, Sweden.
- Department of Women's and Children's Health, Karolinska Institute, Stockholm, Sweden.
ORCID-Profile: Erik Wejryd
Förderung
- Forskningsrådet i Sydöstra Sverige
- Region Östergötland
- Ekhagastiftelsen
- BioGaia
- Svenska Läkaresällskapet
- Vetenskapsrådet
- Svenska Sällskapet för Medicinsk Forskning
Zitieren
APA
Wejryd, E., Marchini, G., Bang, P., Jonsson, B., Ådén, U., & Abrahamsson, T. (2025). Neurodevelopment and Growth 2 Years After Probiotic Supplementation in Extremely Preterm Infants: A Randomised Trial. Acta Paediatrica. https://doi.org/10.1111/apa.70030
Vancouver
Wejryd E, Marchini G, Bang P, Jonsson B, Ådén U, Abrahamsson T. Neurodevelopment and Growth 2 Years After Probiotic Supplementation in Extremely Preterm Infants: A Randomised Trial. Acta Paediatrica. 2025. doi:10.1111/apa.70030
BibTeX
@article{Wejryd2025,
author = {Wejryd, Erik and Marchini, Giovanna and Bang, Peter and Jonsson, Baldvin and Ådén, Ulrika and Abrahamsson, Thomas},
title = {Neurodevelopment and Growth 2 Years After Probiotic Supplementation in Extremely Preterm Infants: A Randomised Trial},
journal = {Acta Paediatrica},
year = {2025},
doi = {10.1111/apa.70030}
}
EUVIMED